Cargando…

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells

PURPOSE: The combination of systemic cisplatin with local and regional radiotherapy as primary treatment of head and neck squamous cell carcinoma (HNSCC) leads to cure in approximately half of the patients. The addition of cisplatin has significant effects on outcome, but despite extensive research...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martens-de Kemp, Sanne R., Dalm, Simone U., Wijnolts, Fiona M. J., Brink, Arjen, Honeywell, Richard J., Peters, Godefridus J., Braakhuis, Boudewijn J. M., Brakenhoff, Ruud H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629194/ https://www.ncbi.nlm.nih.gov/pubmed/23613873 http://dx.doi.org/10.1371/journal.pone.0061555

Ejemplares similares

Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck
por: de Boer, D. Vicky, et al.
Publicado: (2017)

Molecular Detection of Minimal Residual Cancer in Surgical Margins of Head and Neck Cancer Patients
por: Graveland, A. Peggy, et al.
Publicado: (2009)

Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death
por: van Harten, Anne M., et al.
Publicado: (2019)

Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells
por: Klaassen, I, et al.
Publicado: (2001)

Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo
por: Welters, M J P, et al.
Publicado: (1999)

A comprehensive assessment protocol including patient reported outcomes, physical tests, and biological sampling in newly diagnosed patients with head and neck cancer: is it feasible?
por: van Nieuwenhuizen, Annette J., et al.
Publicado: (2014)

Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck
por: Wilting, Saskia M, et al.
Publicado: (2009)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

Genetic Classification of Oral and Oropharyngeal Carcinomas Identifies Subgroups with a Different Prognosis
por: Smeets, Serge J., et al.
Publicado: (2009)

Chemotherapy of human head and neck cancer xenografts with three clinically active drugs: cis-platinum, bleomycin and methotrexate.
por: Braakhuis, B. J., et al.
Publicado: (1983)

Potentially novel options for treatment of HPV-attributable head and neck cancer
por: Brakenhoff, Ruud H.
Publicado: (2013)

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study
por: Tibaldi, Carmelo, et al.
Publicado: (2018)

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines
por: Noordhuis, Paul, et al.
Publicado: (2019)

No Evidence for FANCF Gene Silencing in Head-and-Neck Squamous Cell Carcinomas
por: Ameziane, Najim, et al.
Publicado: (2009)

Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines.
por: Welters, M. J., et al.
Publicado: (1998)

Chemopreventive targeted treatment of head and neck precancer by Wee1 inhibition
por: van Harten, Anne M., et al.
Publicado: (2020)

Retinoid metabolism and all-trans retinoic acid-induced growth inhibition in head and neck squamous cell carcinoma cell lines.
por: Braakhuis, B. J., et al.
Publicado: (1997)

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
por: Adema, Auke D, et al.
Publicado: (2014)

Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications
por: van Harten, Anne M., et al.
Publicado: (2021)

Resection Margins in Head and Neck Cancer Surgery: An Update of Residual Disease and Field Cancerization
por: Pierik, Annouk S., et al.
Publicado: (2021)

The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma
por: Nauta, Irene H., et al.
Publicado: (2021)

In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region
por: Kohabir, Kavish A.V., et al.
Publicado: (2023)

Design and recognition of cucurbituril-secured platinum-bound oligopeptides
por: Barbero, Héctor, et al.
Publicado: (2021)

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
por: Adema, Auke D., et al.
Publicado: (2011)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
por: Zhao, Chong, et al.
Publicado: (2016)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck.
por: Thyss, A., et al.
Publicado: (1986)

Platinum: Reusing Constraint Solutions in Bounded Analysis of Relational Logic
por: Zheng, Guolong, et al.
Publicado: (2020)

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer
por: Takekuma, Munetaka, et al.
Publicado: (2015)

Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
por: Dolman, ME (Emmy) M, et al.
Publicado: (2012)

Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin.
por: Stewart, D. J., et al.
Publicado: (1995)

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.
por: Guchelaar, H. J., et al.
Publicado: (1992)

Applicability of hiPSC-Derived Neuronal Cocultures and Rodent Primary Cortical Cultures for In Vitro Seizure Liability Assessment
por: Tukker, Anke M, et al.
Publicado: (2020)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier
por: Sarkisjan, Dzjemma, et al.
Publicado: (2020)

At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma
por: Wondergem, Niels E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iul6660u373rsj0u2bruasre4v